Metraipolis › archive › dc_1bcd1de22602

Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions — Europe PMC PMID:41184856

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41184856
DOI
10.1186/s12943-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-11-08T20:07:12.531Z
SHA-256 of the archived text
3283640592c1e38bff2c078214f9284542f73b30d9d6f0f35506ba3acd6bc8e1
Stable URL of this page
https://metraipolis.com/documento/dc_1bcd1de22602

How to cite

Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions — Europe PMC PMID:41184856 — Europe PMC (en), https://europepmc.org/article/MED/41184856 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1bcd1de22602 (Metraipolis archive dc_1bcd1de22602, sha256 3283640592c1e38bff2c078214f9284542f73b30d9d6f0f35506ba3acd6bc8e1)
BibTeX
@misc{dc1bcd1de22602,
  title = {Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions — Europe PMC PMID:41184856},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41184856},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1bcd1de22602; sha256 3283640592c1e38bff2c078214f9284542f73b30d9d6f0f35506ba3acd6bc8e1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41184856. Agents can read the archived copy with the MCP tool read_document.